Stock SWTX SPRINGWORKS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 30/04/2024 BST 		5-day change 1st Jan Change
46.69 USD +0.52% Intraday chart for SpringWorks Therapeutics, Inc. +6.11% +27.92%
03-12 Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM
03-06 JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating MT

Business Summary

SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.

Number of employees: 305

Sales per Business

USD in Million2022Weight2023Weight Delta
Life-changing Medicines
100.0 %
0 nan % 5 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 nan % 5 100.0 % -

Managers

Managers TitleAgeSince
Saqib Islam CEO
 Chief Executive Officer 54 31/07/17
Daniel Lynch CHM
 Chairman 65 31/12/15
Frank Perier DFI
 Director of Finance/CFO 64 31/07/19
Tai-An Lin CTO
 Chief Tech/Sci/R&D Officer 61 10/09/23
James Cassidy CTO
 Chief Tech/Sci/R&D Officer 65 31/07/21
Badreddin Edris COO
 Chief Operating Officer 37 31/08/18
Kim Diamond IRC
 Investor Relations Contact - 31/07/18
Bhavesh Ashar PRN
 Corporate Officer/Principal 58 21/03/21
Daniel Pichl HRO
 Human Resources Officer 41 31/07/20
Michael Nofi AUD
 Comptroller/Controller/Auditor 53 31/10/19

Members of the board

Members of the board TitleAgeSince
Alan Fuhrman BRD
 Director/Board Member 67 31/07/19
Freda Lewis-Hall BRD
 Director/Board Member 69 31/07/17
Carlos Alban BRD
 Director/Board Member 61 13/07/22
Daniel Lynch CHM
 Chairman 65 31/12/15
Saqib Islam CEO
 Chief Executive Officer 54 31/07/17
Julie Hambleton BRD
 Director/Board Member 66 19/05/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 74,193,558 70,439,695 ( 94.94 %) 133,662 ( 0.1802 %) 94.94 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
14.65 %
10,809,235 14.65 % 532 M $
Vanguard Fiduciary Trust Co.
8.181 %
6,036,542 8.181 % 297 M $
BlackRock Advisors LLC
6.933 %
5,115,529 6.933 % 252 M $
Deep Track Capital LP
5.507 %
4,063,676 5.507 % 200 M $
Deep Track Capital LP
5.507 %
4,063,676 5.507 % 200 M $
Boxer Capital LLC
4.637 %
3,421,541 4.637 % 168 M $
OrbiMed Advisors Private Equity
4.363 %
3,219,359 4.363 % 158 M $
Marshall Wace LLP
4.099 %
3,024,859 4.099 % 149 M $
Maverick Capital Ltd.
3.894 %
2,873,216 3.894 % 141 M $
T. Rowe Price International Ltd.
3.763 %
2,776,570 3.763 % 137 M $

Company contact information

Springworks Therapeutics, Inc.

100 Washington Boulevard

06902, Stamford

+

http://www.springworkstx.com
address SpringWorks Therapeutics, Inc.(SWTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for SpringWorks Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
46.45 USD
Average target price
67.28 USD
Spread / Average Target
+44.85%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SPRINGWORKS THERAPEUTICS, INC. Stock SpringWorks Therapeutics, Inc.
+27.92% 3.42B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.46% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 96.29B
ARGENX SE Stock argenx SE
+2.13% 22.18B
BIONTECH SE Stock BioNTech SE
-15.84% 21.2B
GENMAB A/S Stock Genmab A/S
-9.21% 18.31B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.38B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.65% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.39% 13.97B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+31.35% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SWTX Stock
  4. Company SpringWorks Therapeutics, Inc.